Document:

gtbp_ex42

  Exhibit 4.2

 

CERTIFICATE OF DESIGNATION OF

 

PREFERENCES, RIGHTS AND LIMITATIONS OF

 

SERIES K PREFERRED STOCK OF

 

GT BIOPHARMA, INC.

 

 

GT
BIOPHARMA, INC. (the “Corporation”), a corporation
organized and existing under the General Corporation Law of the
State of Delaware, DOES HEREBY CERTIFY that, pursuant to authority
conferred upon the Board of Directors by the Restated Certificate
of Incorporation of the Corporation, as amended, and pursuant to
the provisions of Section 151 of the General Corporation Law of the
State of Delaware, the Board of Directors, by resolutions adopted
to be effective on February 22, 2021, duly determined that 115,000
of the authorized shares of Preferred Stock, $0.01 par value per
share, of the Corporation shall be designated “Series K
Preferred Stock,” and duly adopted a resolution providing for
the voting powers, designations, preferences and relative,
participating, optional or other rights, and the qualifications,
limitations and restrictions, of the Series K Preferred Stock,
which resolution is as follows:

 

“RESOLVED, that the
Board of Directors, pursuant to the authority vested in it by the
provisions of the Restated Certificate of Incorporation of the
Corporation, as amended, hereby authorizes the issuance of 115,000
shares of Preferred Stock, $.01 par value, of the Corporation (and
fractions thereof in one-one hundredth increments), which shall be
designated as “Series K Preferred Stock” (the
“Series K Preferred Stock”), with each share of Series
K Preferred Stock having a stated value of $1.00 (the “Stated
Value”) and having the following designations, powers,
preferences and relative, participating, optional and other special
rights, and the qualifications, limitations and
restrictions:

 

1.            

Definitions.

 

As used herein, the following terms shall have the following
meanings:

 

(a)            

“Board”
shall mean the Board of Directors of the Corporation

 

(b)            

“Common
Stock” shall mean the Corporation’s common stock, par
value $0.001 per share.

 

(c)            

“Issuance
Date” shall mean the date on which the first share of Series
K Preferred Stock is
issued.

 

(d)            

“Liquidation”
shall mean any voluntary or involuntary liquidation, dissolution
or winding-up of the
Corporation.

 

(e)            

“Preferred
Stock” shall mean the Corporation’s preferred stock,
par value $0.01 per share.

 

(f)            

“Securities
Act” shall mean the Securities Act of 1933, as
amended.

 

2.            

Rank. The Series K Preferred
Stock will rank on parity to any class or series of our capital
stock hereafter created specifically ranking by its terms on parity
with the Series K Preferred Stock.

 

 

 

 

3.            

Dividends. Shares of Series K
Preferred Stock will not be entitled to receive any dividends,
unless and until specifically declared by our board of directors.
The holders of the Series K Preferred Stock will participate, on an
as-if-converted-to-common stock basis (without giving effect to the
“Beneficial Ownership Limitation” set forth in Section
6L), in any dividends to the holders of common stock.

 

4.            

Voting Rights. Shares of Series
K Preferred Stock will have the same voting rights as shares of
common stock with each share of Series K Preferred Stock entitled
to vote on an as-converted basis (after giving effect to the
“Beneficial Ownership Limitation” set forth in Section
6L) at a meeting of the shareholders of the
Corporation.

 

5.            

Liquidation Preference. In the
event of our liquidation, dissolution or winding up, holders of the
Series K Preferred Stock will have a liquidation preference equal
to $0.01 per share of Series K Preferred Stock and thereafter shall
be on parity with the holders of our common stock and will
participate, on an as-if-converted-to-common stock basis (without
giving effect to the “Beneficial Ownership Limitation”
set forth in Section 6L), in any distributions to the holders of
common stock.

 

6.            

Conversion Rights. The holders
of shares of Series K Preferred Stock shall have the following
conversion rights:

 

A.            

Conversion Rate. Each share of the
Series K Preferred Stock is convertible into 100 shares of Common
Stock (the “Conversion Rate”) at any time at the option
of the holder.

 

B.            

Upon Extraordinary Common Stock Event.
Upon the happening of an Extraordinary Common Stock Event, shares
of Series K Preferred Stock shall be impacted in the same way our
shares of common stock were impacted by the Extraordinary Common
Stock Event. An “Extraordinary Common Stock Event”
shall mean: (i) the issuance of additional shares of Common Stock
as a dividend or other distribution on the outstanding shares of
Common Stock, (ii) the subdivision of outstanding shares of Common
Stock into a greater number of shares of Common Stock, or (iii) the
combination of the outstanding shares of Common Stock into a
smaller number of shares of Common Stock, in each case other than
pursuant to a transaction provided for in Section 6C or
6D.

 

C.            

Capital Reorganization or
Reclassification. If the shares of Common Stock issuable
upon conversion of Series K Preferred Stock shall be changed into
the same or a different number of shares of any class or classes of
stock, whether by reorganization, reclassification or otherwise
(other than a subdivision or combination of shares or stock
dividend provided for in Section 6B, or a reorganization, merger,
consolidation or sale of assets provided for in Section 6D), then
and in each such event, the holders of shares of Series K Preferred
Stock shall have the right thereafter to convert such shares into
the kind and amount of shares of stock and other securities and
property receivable upon such reorganization, reclassification or
other change by the holders of the number of shares of Common Stock
into which such shares of Series K Preferred Stock were convertible
immediately prior to such reorganization, reclassification or other
change, all subject to further adjustment as provided
herein.

 

D.            

Reorganization, Merger or
Consolidation. If at any time or from time to time there
shall be a reorganization, reclassification or recapitalization of
the capital stock (other than a subdivision, combination,
reorganization, reclassification or exchange of shares provided for
elsewhere in this Section 6) (a “Reorganization”), then
as a part of such Reorganization, provision shall be made so that
each holder of Series K Preferred Stock shall thereafter be
entitled to receive upon conversion of such shares of Series K
Preferred Stock, the number of shares of stock or other securities
or property to which a holder of the number of shares of Common
Stock into which such holder’s shares of Series K Preferred
Stock were convertible immediately prior to such Reorganization
would have been entitled upon consummation of such Reorganization.
In any such case, appropriate adjustment shall be made in the
application of the provisions of this Section 6 with respect to the
rights of the holders of Series K Preferred Stock after the
Reorganization to the end that the provisions of this Section 6
(including adjustment of the Conversion Value then in effect, and
the number of shares of Common Stock issuable upon conversion of
the Series K Preferred Stock) shall be applicable after that event
in as nearly equivalent a manner as may be
practicable.

 

 

 

 

E.            

Exercise of Conversion Privilege. To
exercise the conversion right set forth in Section 6A, a holder of
shares of Series K Preferred Stock shall surrender the certificates
representing the shares being converted to the Corporation at its
principal office, and shall give written notice to the Corporation
at that office that such holder elects to convert such shares. Such
notice shall also state the name or names (with address or
addresses) in which the certificates for shares of Common Stock
issuable upon such conversion shall be issued. The certificates for
shares of Series K Preferred Stock surrendered for conversion shall
be accompanied by proper assignment thereof to the Corporation or
in blank. The date when such written notice is received by the
Corporation, together with the certificates representing the shares
of Series K Preferred Stock being converted, shall be deemed the
“Conversion Date.” As promptly as practicable after the
Conversion Date, the Corporation shall issue and deliver
certificates to each holder of shares of Series K Preferred Stock
so converted, or on its written order, such certificates as it may
request, for the number of whole shares of Common Stock issuable
upon the conversion of such shares of Series K Preferred Stock in
accordance with the provisions of this Section 6, and cash as
provided in Section 6J, in respect of any fraction of a share of
Common Stock issuable upon such conversion. Such conversion shall
be deemed to have been effected immediately prior to the close of
business on the Conversion Date, and at such time the rights of the
holder as holder of the converted shares of Series K Preferred
Stock shall cease and the person or persons in whose name or names
any certificates for shares of Common Stock shall be issuable upon
such conversion shall be deemed to have become the holder or
holders of record of the shares of Common Stock represented
thereby.

 

F.            

Cash in Lieu of Fractional Shares. No
fractional shares of Common Stock or scrip representing fractional
shares shall be issued upon any conversion of shares of Series K
Preferred Stock. Instead of any fractional shares of Common Stock
which would otherwise be issuable upon conversion of shares of
Series K Preferred Stock, the Corporation shall pay to the holder
of shares of Series K Preferred Stock which were converted a cash
adjustment in respect of such fractional shares in an amount equal
to the same fraction of the Market Price per share of the Common
Stock at the close of business on the Conversion Date. The
determination as to whether or not any fractional shares are
issuable shall be based upon the total number of shares of Series K
Preferred Stock so converted at any one time by any holder thereof,
and not upon each share of Series K Preferred Stock so
converted.

 

G.            

Partial Conversion. In the event some
but not all of the shares of Series K Preferred Stock represented
by a certificate surrendered by a holder are converted, the
Corporation shall execute and deliver to or on the order of the
holder, at the expense of the Corporation, a new certificate
representing the number of shares of Series K Preferred Stock which
were not converted.

 

H.            

Reservation of Common Stock. The
Corporation shall at all times reserve and keep available out of
its authorized but unissued shares of Common Stock, solely for the
purpose of effecting the conversion of shares of Series K Preferred
Stock, such number of shares of Common Stock as shall from time to
time be sufficient to effect the conversion of all outstanding
shares of Series K Preferred Stock, and if at any time the number
of authorized but unissued shares of Common Stock shall not be
sufficient to effect the conversion of all then outstanding shares
of Series K Preferred Stock, the Corporation shall take such
corporate action as may be necessary to increase its authorized but
unissued shares of Common Stock to such number of shares as shall
be sufficient for such purpose.

 

I.            

No Reissuance of Series K Preferred
Stock. Shares of Series K Preferred Stock which are
converted into shares of Common Stock as provided herein shall not
be reissued.

 

J.            

Issue Tax. The issuance of certificates
for shares of Common Stock upon conversion of any shares of Series
K Preferred Stock shall be made without charge to the holders
thereof for any issuance tax in respect thereof; provided that the
Corporation shall not be required to pay any tax which may be
payable in respect of any transfer involved in the issuance and
delivery of any certificate in a name other than that of the holder
of the shares of Series K Preferred Stock which are being
converted.

 

 

 

 

K.            

Closing of Books. The Corporation will
at no time close its transfer books against the transfer of any
shares of Series K Preferred Stock or of any shares of Common Stock
issued or issuable upon the conversion of any shares of Series K
Preferred Stock in any manner which interferes with the timely
conversion of such shares of Series K Preferred Stock, except as
may otherwise be required to comply with applicable securities
laws.

 

L.            

Beneficial Ownership Limitation. The
Corporation shall not effect any conversion of the Series K
Preferred Stock, and a Holder shall not have the right to convert
any portion of the Preferred Stock, to the extent that, after
giving effect to the conversion set forth on the applicable Notice
of Conversion, such Holder (together with such Holder’s
Affiliates, and any Persons acting as a group together with such
Holder or any of such Holder’s Affiliates (such Persons,
“Attribution Parties”)) would beneficially own in
excess of the Beneficial Ownership Limitation (as defined below).
For purposes of the foregoing sentence, the number of shares of
Common Stock beneficially owned by such Holder and its Affiliates
and Attribution Parties shall include the number of shares of
Common Stock issuable upon conversion of the Series K Preferred
Stock with respect to which such determination is being made, but
shall exclude the number of shares of Common Stock which are
issuable upon (i) conversion of the remaining, unconverted Stated
Value of Preferred Stock beneficially owned by such Holder or any
of its Affiliates or Attribution Parties and (ii) exercise or
conversion of the unexercised or unconverted portion of any other
securities of the Corporation subject to a limitation on conversion
or exercise analogous to the limitation contained herein
(including, without limitation, the Preferred Stock or the
Warrants) beneficially owned by such Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the
preceding sentence, for purposes of this Section 6L, beneficial
ownership shall be calculated in accordance with Section 13(d) of
the Exchange Act and the rules and regulations promulgated
thereunder. To the extent that the limitation contained in this
Section 6L applies, the determination of whether the Preferred
Stock is convertible (in relation to other securities owned by such
Holder together with any Affiliates and Attribution Parties) and of
how many shares of Preferred Stock are convertible shall be in the
sole discretion of such Holder, and the submission of a Notice of
Conversion shall be deemed to be such Holder’s determination
of whether the shares of Preferred Stock may be converted (in
relation to other securities owned by such Holder together with any
Affiliates and Attribution Parties) and how many shares of the
Preferred Stock are convertible, in each case subject to the
Beneficial Ownership Limitation. To ensure compliance with this
restriction, each Holder wall be deemed to represent to the
Corporation each time it delivers a Notice of Conversion that such
Notice of Conversion has not violated the restrictions set forth in
this paragraph and the Corporation shall have no obligation to
verify or confirm the accuracy of such determination. In addition,
a determination as to any group status as contemplated above shall
be determined in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder. For purposes
of this Section 6L, in determining the number of outstanding shares
of Common Stock, a Holder may rely on the number of outstanding
shares of Common Stock as stated in the most recent of the
following: (i) the Corporation’s most recent periodic or
annual report filed with the Commission, as the case may be, (ii) a
more recent public announcement by the Corporation or (iii) a more
recent written notice by the Corporation or the Transfer Agent
setting forth the number of shares of Common Stock outstanding.
Upon the written or oral request (which may be via email) of a
Holder, the Corporation shall within two Trading Days confirm
orally and in writing to such Holder the number of shares of Common
Stock then outstanding. In any case, the number of outstanding
shares of Common Stock shall be determined after giving effect to
the conversion or exercise of securities of the Corporation,
including the Preferred Stock, by such Holder or its Affiliates or
Attribution Parties since the date as of which such number of
outstanding shares of Common Stock was reported. The
“Beneficial Ownership Limitation” shall be 9.99% of the
number of shares of the Common Stock outstanding immediately after
giving effect to the issuance of shares of Common Stock issuable
upon conversion of Series K Preferred Stock held by the applicable
Holder. A Holder, upon notice to the Corporation, may increase or
decrease the Beneficial Ownership Limitation provisions of this
Section 6L applicable to its Preferred Stock provided that the
Beneficial Ownership Limitation in no event exceeds 9.99% of the
number of shares of the Common Stock outstanding immediately after
giving effect to the issuance of shares of Common Stock upon
conversion of this Series K Preferred Stock held by the Holder and
the provisions of this Section 6L shall continue to apply. Any such
increase in the Beneficial Ownership Limitation will not be
effective until the 61st day after such notice is delivered to the
Corporation and shall only apply to such Holder and no other
Holder. The provisions of this paragraph shall be construed and
implemented in a manner otherwise than in strict conformity with
the terms of this Section 6L to correct this paragraph (or any
portion hereof) which may be defective or inconsistent with the
intended Beneficial Ownership Limitation contained herein or to
make changes or supplements necessary or desirable to properly give
effect to such limitation. The limitations contained in this
paragraph shall apply to a successor holder of Preferred
Stock.

  

 

 

 

7.            

Miscellaneous.

 

(a)         

The Corporation
covenants that all shares of Common Stock which may be issued upon
conversions of shares of Series K Preferred Stock will upon
issuance be duly and validly issued, fully paid and nonassessable,
free of all liens and charges and not subject to any preemptive
rights.

 

(b)         

No share or shares
of Series K Preferred Stock acquired by the Corporation by reason
of redemption, purchase, conversion or otherwise, shall be
reissued, and all such shares shall be cancelled, retired and
eliminated from the shares which the Corporation shall be
authorized to issue.”

 

The
number of shares of Series K Preferred Stock authorized is 115,000,
none of which have been issued.

 

IN
WITNESS WHEREOF, this Certificate of Designation has been signed by
an authorized officer of the Corporation as of the date first
written above.

 

 

By:            

/s/ Anthony
Cataldo             

Name:
Anthony Cataldo

Title:
Chief Executive OfficerEX-10.24

 Exhibit 10.24 

DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), effective as of May 2, 2016 (the “Effective Date”), between GLYTECH
LLC, a Delaware limited liability company with offices at 2711 Centerville Road, Wilmington, DE, as licensor (“Glytech”), and NEURORX, INC., a corporation organized under the laws of the State of Delaware, with offices at 913 North Market
Street, Suite 200, Wilmington, DE, as licensee (“NeuroRx”). 
 Glytech possesses certain proprietary information and technology
related to rapid-onset therapy for treatment resistant depression (collectively, and as more definitively described below, the “Licensed Technology”). 

NeuroRx wishes to acquire, and Glytech desires to grant to NeuroRx, a license to the Licensed Technology to research, develop, manufacture,
have manufactured, sell, have sold and market products utilizing the Licensed Technology and to provide related Know-How, on the terms and conditions set forth herein. 

Glytech and NeuroRx have agreed on a three-phase development strategy, consisting of an initial financing round and a second financing round,
both of which have occurred prior to the Effective Date, followed by a larger financing round, which financing rounds were and will be led by Dr. Jonathan C. Javitt as the initial Chief Executive Officer of NeuroRx. 

NOW, THEREFORE, for good and valuable consideration, the sufficiency of which is hereby acknowledged, and for the mutual promises and
covenants disclosed herein, the parties agree as follows: 
 1.     Amended and Restated Agreement; Definitions

 1.1     Amended and Restated Agreement. The parties acknowledge and agree that, as of the
Effective Date, this Agreement replaces and supersedes any prior agreement between the parties or their respective Affiliates relating to the subject matter hereof, including without limitation the Development and License Agreement (the
“Original License Agreement”) dated as of August 6, 2015 (the “Original Effective Date”) between Glytech and Neurotech Inc, predecessor to NeuroRx, In the event of a conflict between this Agreement and the Original License
Agreement, or any such other prior agreements, the terms and conditions of this Agreement shall control. 

1.2     Definitions. The defined terms used in this Agreement shall have the meanings
ascribed to them herein or as set forth on Schedule A. 
 2.     Exclusive License Grant. 

2.1     Grant of License. (i) License. Subject to and conditioned upon Section 2.3(c) of this
Agreement, Glytech hereby grants to NeuroRx an irrevocable, perpetual, exclusive (even as to Glytech) royalty-free license with the right to sublicense, under the Licensed Technology and for the Term to research, develop, make, have made, use, sell,
offer for sale, export, import and otherwise commercialize the Products in the Territory in the Field. The license granted herein does not include any license with respect to the Excluded Technologies or the Excluded Claims. 

 (ii)     Commercial Diligence. NeuroRx shall use
Commercially Reasonable Efforts to develop and commercialize the Products. For purposes of this Agreement, “Commercially Reasonable Efforts” shall mean, with respect to activities that a party is required to perform hereunder, the level of
effort that would generally be used by a similarly situated pharmaceutical company to conduct such activities with respect to a product of similar market potential and profit potential to such party, taking into account issues of safety and
efficacy, approved labelling, product profile, the patent and other proprietary position, the then current competitive environment, the return on investment potential, the regulatory environment, and other relevant scientific, technical and
commercial factors, in each case as measured by the facts and circumstances at the time such efforts are due. 

(iii)     Right of First Negotiation for Excluded Technology. For the
Term of this Agreement, Glytech hereby grants to NeuroRx an option to negotiate an exclusive worldwide, commercial license for use in the Field, with a right to sublicense, through good faith negotiations on commercially reasonable terms, to any
Excluded Technology (the “NeuroRx Option”). This option to negotiate the license shall be exercisable upon written notice to Glytech. Should Glytech wish to divest, license or otherwise transfer rights in any Excluded Technology or
Excluded Claims for use in the Field to a third party, Glytech must first inform NeuroRx in writing and NeuroRx will have fifteen (15) days following receipt of such written notice to exercise the NeuroRx Option (“Option Period”),
which Option Period can be extended by mutual written agreement of the parties. If the Parties are unable to reach agreement in principle within sixty (60) days after the date upon which NeuroRx exercises the NeuroRx Option, then Glytech will
be free to offer such rights to third parties. 
 (iv)     Right to Purchase Excluded
Technology. NeuroRx shall have the option at its sole discretion to purchase the Excluded Technology from Glytech for a single payment of $25 million (twenty five million dollars) until the
3rd anniversary of the Original Effective Date and for a single payment of $50 million (fifty million dollars) until the 5th anniversary
of the Original Effective Date (the “NeuroRx Purchase Option”). 
 2.2     Restrictions. During the
Term, Glytech shall not directly or indirectly, grant, license, assign, alienate or otherwise dispose of or grant any of its rights in the Licensed Technology to any third parties in a manner that would impair or be in breach of NeuroRx’s
rights under this Agreement, or enter into any collaboration or license agreement with any third party in connection with the research, development or commercialization in the Field of a Product formulated using the Licensed Technology. Glytech
shall not (and shall use reasonable best efforts to cause its other Affiliates and agents not to), directly or indirectly, research, develop or commercialize a product that is competitive with the Product in the Territory for use in the Field.
NeuroRx acknowledges (i) that the foregoing restrictions do not limit the ability of Glytech as to the exploitation, development or commercialization of the Excluded Technologies or the Excluded Claims or any product related thereto, except as
to NeuroRx’s right of first negotiation referred to in Section 2.1 of this Agreement, or for use thereof outside of the Field, and (ii) that the foregoing restrictions do not affect Glytech’s ability or rights to sell, transfer
or otherwise assign the Licensed Technology to other Persons so long as such sale, transfer or assignment does not modify or impair NeuroRx’s rights under this Agreement. 

  
 2 

 2.3     Financial Terms. In full consideration of the License,
Glytech shall receive the following, and the parties agree to the following financial arrangements: 
 a)    
Equity in NeuroRx – NeuroRx shall issue to Glytech that number of shares of common stock of NeuroRx, or such other form of equity security that is or will be issued to the other founders of NeuroRx, their designees and
Affiliates, representing 50% of the initial voting power and equity ownership interests of NeuroRx, without taking into account any outside investments (the “Glytech Shares”). The shares of common stock or other securities held by the
other founders, their designees and Affiliates (the “Other Founders’ Shares”), together with Glytech Shares, will constitute 100%, on a fully diluted basis, of the outstanding “founders’” equity interests of NeuroRx.
NeuroRx represents and warrants that the Glytech Shares will be duly and validly issued, fully paid and non-assessable shares of equity securities of NeuroRx, and, when issued, will represent 50% of the issued and outstanding capital stock of
NeuroRx, on a fully diluted basis. Glytech may assign all or a portion of the Glytech Shares to Dr. Daniel C. Javitt (“DCJ”) and/or members of his immediate family, and their respective Affiliates without limits, and may at
Glytech’s sole discretion assign up to 10% to to-be-determined 3rd parties, provided that all such parties sign a joinder agreement to the NeuroRx Shareholder’s Agreement and
Registration Rights Agreement in the same form already signed by Glytech. Subsequent financings have diluted, and future financings, including the Third Financing Round, will dilute, the Glytech Shares and the Other Founders’ Shares pro rata.

 b)     Requirement to complete Third Financing Round. Should the Third
Financing Round not close by the fifth anniversary of the Original Effective Date of this agreement, NeuroRx and Jonathan Javitt have agreed that 3.750,000 shares of the original 5,000,000 shares issued to the Jonathan Javitt Living Trust shall be
transferred to Glytech, and Glytech will then have the right to appoint both the Glytech Director and the Other Founding Director. Such share transfer and appointment shall not occur if NeuroRx has received cash payments of at least $30 mm (other
than for the reimbursement of out of pocket patent and research and development expenses) from one or more sublicenses, development agreements or collaborative or corporate partnering agreements, on terms reasonably satisfactory to Glytech. 

c)     Repayment of Glytech loan. NeuroRx shall pay to Glytech funds advanced, in the amount
of $250,000 (the “Glytech Loan”), as reimbursement for patent and related development expenses incurred by Glytech in connection with its initial development of the Licensed Technology, to be paid as follows: $100,000 simultaneously
herewith in connection with the execution of this Agreement, and $150,000 upon the closing of the earlier of (x) the Third Financing Round or (y) the third anniversary of the Original Effective Date. 

d)     Assumption of Costs. Concomitant with the signing of this agreement, NeuroRx shall assume
responsibility for payment of all prior as well as all ongoing patent prosecution costs and related costs required to perfect the Licensed Technology and the intellectual property rights to the licensed technology (by payment thereof directly or by
prompt reimbursement to Glytech). The obligations of NeuroRx hereunder are in addition to its other payment obligations under this Agreement. Any costs borne by Glytech and not reimbursed within 30 days of invoicing to NeuroRx shall bear the Late
Payment Fee, as defined herein. 

  
 3 

 e)    No Royalties; Paid Up License.
The License provided herein by Glytech to NeuroRx shall be royalty-free. 
 f)     Scientific Advisory
Board – Until the closing of the Third Financing Round, Dr. Daniel C. Javitt, the Chief Executive Officer of Glytech, will serve as the Chairman of NeuroRx’s Scientific Advisory Board. In such capacity, he will have
executive authority on publication decisions relating to the Licensed Technology and other technology and products to be developed by NeuroRx, with respect to content, timing of publication and authorship. Additionally, he shall be informed of and
have the right to attend (in person or by conference call) all meetings of NeuroRx personnel with the FDA, other regulatory agencies, CRO’s, and other contract manufacturers and subcontractors, and shall be reimbursed for his reasonable out of
cost expenses incurred in connection therewith. At NeuroRx’s election in its sole discretion, Dr. Daniel Javitt will continue to serve in this capacity beyond the closing of the Third Financing round. 

g)     Support Payments. During the Term, NeuroRx shall pay Glytech a support payment (the “Support
Payment”) of $100,000 per year (payable monthly) for its continued development of the Licensed Patents and assistance with the preparation of FDA filings and clinical protocol development.     The Support Payment will be
increased to $250,000 per year upon the closing of the Third Financing Round. NeuroRx shall also reimburse Glytech for reasonable documented travel expenses in connection with such support efforts, including up to $50,000 per year to support travel
to meetings related to patent prosecutions. Any obligations hereunder not timely paid within 30 days shall bear the Late Payment Fee. 

h)     Expense Reimbursement. NeuroRx shall reimburse Glytech for its out-of-pocket legal expenses, up to a
maximum of $15,000, incurred in the drafting, negotiation and execution of this Agreement and the Original License Agreement. 
 3.
    Intellectual Property Rights. 
 3.1     Ownership of Inventions. The Parties
acknowledge and agree that any and all rights in the Licensed Technology in existence as of the Effective Date of this Agreement shall, as between Glytech and NeuroRx, be the sole and exclusive property of Glytech (“Glytech IP”). All
future inventions, patentable or not, which are jointly conceived or reduced to practice by employees or representatives of Glytech related to the Licensed Technology, shall be the property of Glytech, and shall be subject to the license grant to
NeuroRx under this Agreement, without additional consideration. 

  
 4 

 3.2     Patent Filings. Glytech shall have the right, at its sole
discretion, to prepare, file, prosecute, maintain and (subject to Section 3.3 of this Agreement) defend the Licensed Patent Rights, including any additional patent applications Glytech may, in its discretion, elect to file in any jurisdiction
in the Territory, and Glytech shall be responsible for related interference, derivation and other pre and post-grant proceedings. Glytech shall confer with NeuroRx regarding the preparation, filing, prosecution, maintenance and defense of any
Licensed Patent Rights, and shall consider any input from NeuroRx relating thereto. Notwithstanding anything to the contrary in this Section 3.2, NeuroRx shall have the right, at its sole discretion, to undertake and conduct the defense of any
Licensed Patent Rights upon written notice to Glytech (the “Defense Right”), and shall bear 100% of the costs and expenses thereof. If NeuroRx does not exercise its Defense Right, then NeuroRx will reimburse Glytech for 75% of
Glytech’s reasonable out-of-pocket costs involved in defense of any Licensed Patent Right. NeuroRx will reimburse Glytech for 75% of Glytech’s reasonable out-of-pocket costs involved in the preparation, prosecution and maintenance of the
Licensed Patent Rights (including without limitation the reasonable costs and expenses of patent counsel). At NeuroRx’s request, Glytech will apply for divisional or continuation applications reciting solely the Licensed Technology in
jurisdictions where this is permissible without affecting Glytech’s rights to the Excluded Technology. In such cases, NeuroRx shall bear 100% of the expenses relating to preparation, filing, prosecution, maintenance and defense of such
divisional or continuation Licensed Patent Rights. All Licensed Patent Rights shall remain property of Glytech. Filing of additional patent applications shall not alter the terms of the grant of license as set forth in Section 2.1 of this
Agreement. 
 3.3     Infringment. NeuroRx shall have the primary right, but not the obligation, to institute,
prosecute and control any action or proceeding with respect to any suspected or actual infringement or misappropriation by a third party of any Licensed Technology, using counsel of its own choice reasonably satisfactory to Glytech, at its own
expense. Glytech shall cooperate with NeuroRx (but at NeuroRx’s expense) in the prosecution of such action or proceeding. Notwithstanding anything in the contrary in Section 3.2 of this Agreement, if any action instituted by NeuroRx
pursuant to this Section 3.3 involves defense of the validity, enforceability or any other aspect of any Licensed Technology, by counterclaim or otherwise, then NeuroRx shall have the right to control, prosecute, terminate and/or settle such
defense as if it were an action initiated by NeuroRx under this Section 3.3, upon reasonable prior consultation with Glytech. If NeuroRx or any relevant court or tribunal determines that Glytech is an indispensable party to the action, Glytech
hereby consents to be joined to such action, and any settlement of such action cannot be made without the consent of Glytech, which will not be unreasonably withheld (provided that NeuroRx shall pay all costs and expenses of Glytech, including
without limitation the payment of any settlements or judgments). Any recovery in any such action shall be applied first towards the reimbursement of any attorney’s fees and costs and expenses of the action, and shall thereafter shall be shared
equally by the Parties. If Glytech desires to institute, prosecute and control any action or proceeding with respect to infringement or misappropriation by a third party of any Licensed Technology that NeuroRx declines or fails to institute,
prosecute or control, Glytech may do so at its own expense after reasonable written notice to NeuroRx and with input from NeuroRx which shall be reasonably considered, and any recovery in any such action shall be applied first towards the
reimbursement of any attorney’s fees and costs and expenses of the action, and thereafter shall belong exclusively to Glytech. 

  
 5 

 3.4 Additional Obligations of NeuroRx. For so long as the NeuroRx Purchase Option is
outstanding and without limitation to the 5th anniversary of the Original Effective Date, (i) all references in Section 3.2 to “Licensed Patent Rights” shall be replaced by the
phrase “Glytech Patent Rights”, which shall include both the Licensed Patent Rights and all other Patent Rights of Glytech covering any Excluded Claims or Excluded Technologies, (ii) all references in Section 3.3 to
“”Licensed Technology” shall be replaced by the phrase “Glytech Technology”, which shall consist of any Licensed Technology as well as any Excluded Technology, (iii) all references in Section 3.2 to 75% shall be
replaced by “100%”, (iv) the phrase “NeuroRx shall have the primary right, but not the obligation,” in the first sentence of Section 3.3 shall be replaced by the phrase “NeuroRx shall have the obligation”; and
(v) the phrase “then NeuroRx shall have the right” in the third sentence of Section 3.3 shall be replaced by the phrase “then NeuroRx shall have the obligation”. 

4.     Corporate Governance. 

4.1     Board of Directors. Until the closing of the Third Financing Round, Glytech shall be entitled to elect one
(1) director of NeuroRx (the “Glytech Director”). The holders of the Other Founder’s Shares, by majority vote, shall be entitled to elect one (1) director of NeuroRx (the “Other Founding Director”). Any director
elected as provided in the preceding sentences may be removed without cause by, and only by, the affirmative vote of the holders of the Glytech Shares, in the case of the Glytech Director, or by the holders of the Other Founders’ Shares, in the
case of the Other Founding Director. At any meeting held for the purpose of electing a director, the presence in person or by proxy of the holders of a majority of the outstanding shares of the class, classes, or series entitled to elect such
director shall constitute a quorum for the purpose of electing such director. 
 4.2     Protective Provisions.
For so long as Glytech is entitled to elect the Glytech Director pursuant to the provisions of Section 4.1, no action by the Board of Directors with respect to the following matters may be taken without the approval of the Glytech Director:

  

	 	(a)	 increase the base salary or incentive compensation of the Chief Executive Officer of NeuroRx or any Affiliate
above $275,000 per year; 

  

	 	(b)	 enter into any other type of transaction with the Chief Executive Officer of NeuroRx or any Affiliate;

  

	 	(c)	 increase the size of the Board of Directors of NeuroRx; 

 

	 	(d)	 [intentionally omitted]; 

 

	 	(e)	 [intentionally omitted]; 

 

	 	(f)	 purchase, build or otherwise acquire any capital asset, investment or real property, the purchase price or
value of which will exceed $50,000; 

  

	 	(g)	 enter into any agreement or series of related agreements, including any agreement to borrow money, that, either
individually or collectively, creates a monetary obligation greater than $150,000; 

  
 6 

	 	(h)	 loan NeuroRx funds to, or guaranty any obligation or liability of, any shareholder, officer or director of
NeuroRx, or grant a security interest in any assets of NeuroRx in an amount greater than $50,000; 

  

	 	(i)	 enter into any license or sublicense, development agreement, CRO agreement, joint venture agreement,
collaborative or corporate partnering agreement, or similar agreement involving the Licensed Technology; 

  

	 	(j)	 issue any securities of NeuroRx, other than in connection with the Third Financing Round or in accordance with
a stock option or other equity incentive compensation plan approved by the Glytech Director; 

  

	 	(k)	 adopt a stock option plan or other equity compensation plan, and make any grants thereunder to employees,
consultants, advisors, shareholders, officers or directors; 

  

	 	(l)	 enter into any transaction involving a Change of Control; 

 

	 	(m)	 dissolve or wind up NeuroRx; 

 

	 	(n)	 establish any pension, benefit and incentive plans for any or all current or former shareholders, employees,
officers, directors and/or any of NeuroRx or make any payments pursuant thereto; 

  

	 	(o)	 make an assignment for the benefit of creditors of NeuroRx, file a voluntary petition in bankruptcy, or consent
to the appointment of a receiver for NeuroRx; or 

  

	 	(p)	 amend the Articles of Organization or similar corporate organizational documents of NeuroRx.

 4.3     Information Rights. For so long as Glytech holds any Glytech Shares, and until the
Third Financing Round, Glytech shall have the right to review all information relating to the Company, including without limitation its books and records, account ledgers and financial and bank information, at reasonable times and on reasonable
advance notice, in addition to the right to receive all reports, presentations and information otherwise made available to the directors and/or stockholders of NeuroRx, subject in all instances to the confidentiality provisions of Section 5.
Following the closing of the Third Financing Round, Glytech shall have the information rights then possessed by other stockholders of NeuroRx. 

4.4     Late payments: All payments due to Glytech from NeuroRx shall be paid within 30 days of invoice date.
Interest shall accrue on any unpaid amounts due at a rate equal to the lesser of (i) 10% per annum or (ii) the maximum rate permitted by applicable law, compounded quarterly (the “Late Payment Fee”) 

  
 7 

 5.     Confidentiality 

5.1.     During the Term of this Agreement, Glytech and/or NeuroRx, as the case may be, may receive Confidential
Information belonging to the other Party. In consideration of the disclosure of Confidential Information, the Parties undertake as follows: 
  

	 	(1)	 The party receiving Confidential Information (the “Receiving Party”) shall use Confidential
Information only in connection with the purposes of this Agreement. 

  

	 	(2)	 The Receiving Party shall not disclose Confidential Information to any third party without the prior written
consent of the party disclosing such Confidential Information (the “Disclosing Party”), which consent shall not be unreasonably withheld. Such third party shall enter into confidentiality obligations not less strict than those set out
herein in a form reasonably acceptable to the Disclosing Party. The Receiving Party shall be responsible for insuring that its employees and Affiliates and consultants shall keep any Confidential Information provided to them confidential, and that
any consultants shall consent to confidentiality obligations not less strict than those set out herein in a form reasonably acceptable to the Disclosing Party. Disclosure of Confidential Information by a Receiving Party to its employees, Affiliates,
consultants and permitted third parties shall be made only if any such parties need to know Confidential Information in order to effectuate the purposes of this Agreement. 

 

	 	(3)	 Upon termination of the Term, the Receiving Party shall return or destroy, as per request of the Disclosing
Party, any documents (including computer data) and samples relating to Confidential Information received from the Disclosing Party under this Agreement, except for one copy which is to be retained in a confidential central file for archival purposes
only. 

 5.2.    The obligations of a Receiving Party under Section 5.1 shall not apply to: 

 

	 	(1)	 Confidential Information which is or becomes part of the public domain other than through violation of this
Agreement by the Receiving Party; 

  

	 	(2)	 Information corresponding to Confidential Information received by the Receiving Party from a third party who is
under no obligation of confidence to the Disclosing Party; or 

  

	 	(3)	 Information corresponding to Confidential Information which the receiving Party can demonstrate was in its
possession at the time of disclosure or was thereafter independently conceived or developed by employees or agents of the Receiving Party having no direct or indirect knowledge of the Confidential Information disclosed. 

5.3     The Parties may disclose Confidential Information if requested pursuant to an order of a competent court or
administrative agency, provided that the Party subject to such order has informed the other Party thereof in writing, and has used reasonable efforts to limit the scope of the disclosure and to obtain confidential treatment by the court or
administrative agency of Confidential Information disclosed pursuant to such order. 

  
 8 

 5.4     The obligations under this Article 5 shall expire five
(5) years after the termination of this Agreement. 
 6.     Representations and Warranties. Each Party
represents to the other that (1) it is duly organized and validly existing under the laws of its jurisdiction of organization, (2) it has all requisite corporate power and corporate authority to enter into this Agreement and to carry out
its obligations hereunder and (3) the execution, delivery and performance of this Agreement will not conflict with or violate its constitutive documents. 

6.1 Representations and Warranties of Glytech. 

(i)     To Glytech’s knowledge, Glytech owns or Controls all right, title and interest in and to the Licensed
Technology and has the right to license the Licensed Technology as contemplated herein, free and clear of any encumbrances. 

(ii)     To Glytech’s knowledge, Glytech is not in material conflict with, or in material default or violation of,
any law or regulation, including those promulgated by the FDA, applicable to the Field or the Licensed Technology. 

(iii)     Glytech makes no representation or warranty as to the validity or enforceability of the Licensed Technology, and
has afforded NeuroRx for its due diligence full access to all requested data and files relating to the Licensed Technology. 

(iv)     Notwithstanding the foregoing, Glytech is not aware of any impediment to the validity or enforceability of the
Licensed Technology that has not been disclosed to NeuroRx and/or patent authorities. 
 (iv)     To Glytech’s
knowledge, no Person is infringing, violating or diluting, in each case, in any material manner, any of the Licensed Technology. Glytech represents that is has not provided any written notice to any Person, and no legal proceeding or claim has been
asserted by Glytech, alleging that any Person is infringing, violating or diluting any of the Licensed Technology anywhere in the Territory. 

(v)     To the knowledge of Glytech, none of the present or contemplated activities to develop and commercialize any
Products infringes, misappropriates, dilutes, or impairs any intellectual property rights of other Persons. Notwithstanding the foregoing, NeuroRx confirms that Glytech has disclosed to NeuroRx the existence of potentially competing intellectual
property rights developed at Herzog Hospital in Israel, including U.S. patent application 20140018349 and foreign counterparts, in which Dr. Daniel C. Javitt, CEO of Glytech, and Dr. Uriel Heresco-Levy are named as co-inventors, and
that NeuroRx has conducted an independent review of such intellectual property rights. The existence of such intellectual property rights shall not be deemed be a breach of Glytech’s representations and warranties hereunder. 

(vi)     Glytech has not received an FDA Warning Letter, Form FDA-483, Untitled Letter or other adverse written
communication from the FDA or any regulatory authority in the Territory regarding, and, to Glytech’s knowledge, there are no facts or circumstances within Glytech’s control that are likely to give rise to (A) any material adverse
change to, or delay in obtaining, any Regulatory Approval; (B) any failure to materially comply with any 

  
 9 

 
laws or any term or requirement of any Regulatory Approval; (C) any revocation, withdrawal, suspension, cancellation, material limitation, termination or material modification of any
Regulatory Approval; or (D) any enforcement action against or effort to enjoin the Glytech, its officers, directors, employees, shareholders or its agents, from conducting its business with respect to a Product. 

(vii)     None of Glytech’s officers, directors, nor, to Glytech’s knowledge, any of their employees, agents,
Affiliates or any consultant involved in any Regulatory Approval, has been debarred or convicted of any felony for which debarment is authorized by 21 U.S.C. Section 335a or any other relevant law, disqualified from participating in clinical
trials pursuant to 21 C.F.R. §312.70, included on the HHS/OIG List of Excluded Individuals/Entities, the General Services Administration’s List of Parties Excluded from Federal Programs, or the FDA Debarment List or has engaged in any
other action for which debarment is authorized by 21 U.S.C. Section 335a or any other relevant law. 
 (viii)    
To Glytech’s knowledge, all preclinical trials in respect of the activities being conducted by or on behalf of Glytech or its Affiliates for producing data submitted to any regulatory authority, including the FDA, in connection with any
Regulatory Approval are being or have been conducted in compliance in all material respects with the required experimental protocols, procedures and controls pursuant to generally accepted good clinical practices and all applicable laws, including
the FDCA. NeuroRx acknowledges that it has received copies of contracts and data related to preclinical research funded by Glytech at Psychogenics, Inc., including data subsequently incorporated into filings for the Licensed Patents submitted by
Glytech, and that NeuroRx has had the opportunity to review such contracts and data to assure compliance with applicable laws and regulations. 

(xi)     Neither Glytech nor any Affiliate has issued or received any safety notices regarding any Product, or has
knowledge of any material complaints with respect to any Product. 
 (xii)     Glytech has made available for
NeuroRx’s review any and all documents in its possession material to assessing NeuroRx’s compliance with the FDCA, and all material written communications received from the FDA or any other regulatory authority during the last three years
in each case with respect to any Product. 
 (xiii)     NeuroRx acknowledges that Glytech also has made available to
NeuroRx and all documents relating to the employment of Dr. Daniel Javitt by Columbia University and the Nathan Kline Institute and his related affiliations with such institutions. NeuroRx acknowledges that notwithstanding anything to the
contrary in this Section 6.1, Dr. Javitt’s and Glytech’s rights to the Licensed Technologies are subject to any agreements with such institutions as well as their respective rules and regulations, all of which have been provided
to, and reviewed by, NeuroRx and its advisors. 
 7.     Term and Termination 

7.1.     This Agreement shall enter into force on the Effective Date and shall continue until terminated pursuant to the
provisions below. 

  
 10 

 7.2     NeuroRx may terminate this Agreement at any time, with immediate
effect, by written notice, if NeuroRx becomes aware of serious adverse events involving any Product. 

7.3    [intentionally omitted] 

7.4     In addition, either Party may terminate this Agreement with immediate effect by giving to the other Party written
notice of termination: 
 (i) upon any material breach of this Agreement by the other Party which is not rectified within thirty
(30) days of the notification thereof; provided, however, that if such breach is not capable of rectification within such thirty (30) day period, the non-breaching Party may not terminate this Agreement so long as the breaching Party is
acting diligently in a commercially reasonable manner to correct such breach; or 
 (ii) if the other Party becomes insolvent or proceedings
in voluntary or involuntary bankruptcy (each a “Bankruptcy”) are instituted on behalf or against such Party (a “Bankrupt Party”); (B) The Parties acknowledge that the Licensed Technology, as well as Inventions, Know-How and
Patent Rights to be developed by NeuroRx (collectively “NeuroRx IP”), each is “intellectual property” for purposes of Section 365(n) of the U.S. Bankruptcy Code; that NeuroRx will have the right to exercise all rights
provided by Section 365(n) with respect to the Licensed Technology in the event of a Glytech Bankruptcy and that Glytech will have the right to exercise all rights provided by Section 365(n) with respect to the NeuroRx IP in the event of a
NeuroRx Bankruptcy. In the event that a Party becomes insolvent or proceedings in voluntary or involuntary bankruptcy are instituted on its behalf and the other Party does not terminate this Agreement, such other Party will have the right to require
the delivery by Bankrupt Party (or in the event of a filing of bankruptcy by or against the Bankrupt Party, by the trustee or receiver) to the other Party of all Licensed Technology or NeuroRx IP, as applicable (including all embodiments thereof).

 7.5    If Glytech terminates this Agreement pursuant to the provisions of Section 7.4(i), then (A) the
License of the Licensed Technologies shall not occur (as provided in Section 2.1) and the restrictions set forth in Section 2.2 shall no longer apply, (B) NeuroRx shall transfer and assign all of its assets to Glytech, including
without limitation the NeuroRx IP and all data and research, in whatever format, relating to the Licensed Technologies and the Products, and (C) Glytech shall relinquish its rights to the Glytech Shares, which shall be cancelled. 

7.6     Termination of this Agreement by either Party shall not affect the rights and obligations of the Parties accrued
prior to the effective date of the termination, including without limitation, any obligations under Section 2.3(c), and Section 3 relating to the reimbursement or payment of patent-related expenses. 

  
 11 

 8.    Indemnification for product liability actions. NeuroRx
hereby agrees to defend, hold harmless and indemnify (collectively “Indemnify”) Glytech and its Affiliates, and its and their agents, members, managers, officers and employees (the “Glytech Indemnitees”) from and against any and
all liability or expense (including without limitation reasonable legal expenses and attorneys’ fees) (collectively “Losses”) resulting from suits, claims, actions and demands, in each case brought by any third party (each, a
“Third-Party Claim”): (i) arising out of NeuroRx’s, or its permitted sublicensee’s, sale or experimental use of products developed from any Know-How, advice or assistance provided by Glytech hereunder; or (ii) arising out of
the death of or injury to any person or persons or out of any damage to property, arising from the development, manufacture, commercialization, storage, handling, use, sale, offer for sale, lease, consumption, advertisement of or importation of any
Product developed from the Glytech Patent Rights or Glytech Technology. NeruroRx’s obligation to Indemnify the Glytech Indemnitees pursuant to the foregoing sentence shall not apply to the extent that any such Losses (A) arise from the
gross negligence or willful misconduct of any Glytech Indemnitee or (B) arise from any breach by Glytech of this Agreement. To be eligible to be Indemnified hereunder, Glytech shall provide NeuroRx with prompt notice of the Third-Party Claim
giving rise to the indemnification obligation pursuant to this Section 8 and the exclusive ability to defend (with the reasonable cooperation of Glytech) or settle any such claim; provided, however, that NeuroRx shall not enter into any
settlement that admits fault or wrongdoing by Glytech or creates any obligation on the part of Glytech without Glytech’s written consent, such consent not to be unreasonably withheld or delayed. Glytech shall have the right to participate, at
its NeuroRx’s expense and with counsel of Glytech’s choice, in the defense of any claim or suit that has been assumed by NeuroRx. 

9.    Notices. Any notice to be given under this Agreement must be in writing and delivered either in person, by
any method of mail (postage prepaid) requiring return receipt, or by overnight courier or facsimile confirmed thereafter by any of the foregoing, to the party to be notified at its address set forth above, or at any address such party has previously
designated by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earliest of: (a) the date of actual receipt; (b) if mailed, five days after the date of postmark; or (c) if delivered
by express courier, the next business day the courier regularly makes deliveries in the country of the recipient. 
 If to NeuroRx: 

NeuroRx, Inc. 
 Jonathan C. Javitt, M.D., CEO

 913 North Market Street 

Wilmington, DE 19801 

jjavitt@neurorxpharma.com  
 If to Glytech:

 Daniel C. Javitt, M.D., Ph.D. 
 c/o Adam
Eilenberg, Esq. 
 11 East 44th Street, Suite 1900 
 New
York, New York 10017 
 djavitt@gmail.com 

  
 12 

 10.    Independent Contractor. For the purposes of this
Agreement, each Party shall be an independent contractor and not an agent or employee of the other Party. Neither Party shall have authority nor power to make any statements, representations or commitments of any kind or to take any action which is
binding on the other Party, except as may be explicitly provided for herein or authorized by the other Party in writing. 

11.    Entire Agreement, Modifications and Amendments. This Agreement, and the exhibits attached hereto, sets forth
the entire understanding between the Parties with respect to the transactions and arrangements contemplated hereby and supersedes all prior oral or written arrangements. No amendment or modification to this Agreement shall be valid or binding upon
the Parties unless made in writing and duly signed by the representatives of both Parties. 
 12.    Severability.
In the event of the invalidity, illegality or unenforceability of any provision of this Agreement, the Parties shall negotiate in good faith, in place of such provision, a valid, legal and enforceable provision which, insofar as possible and
equitable, implements the purposes hereof. The invalidity, illegality or unenforceability of any provision of this Agreement shall not affect or impair in any way the validity, legality or enforceability of the other provisions of this Agreement
unless the invalidity of such provision would result in depriving a party of the essential benefits it receives under this Agreement.. 

13.    Assignment, Subcontracting, Successors and Assigns. This Agreement and all rights and obligations hereunder
are personal to the Parties hereto and may not be assigned or subcontracted without the prior written consent of the other Party hereto, except that either Party shall be entitled to assign this Agreement or any part thereof to its Affiliates or any
Party taking over all or substantially all of its business. Any assignment or subcontracting, or attempt at the same, in violation of this Agreement shall be void and without effect. This Agreement shall be binding upon and shall inure to the
benefit of the permitted successors or permitted assigns of each Party. 
 14.    Waiver. No waiver of any
requirement of this Agreement, whether by conduct or otherwise, shall be effective unless given in writing. No actual or implied waiver by any Party in one or more instances of any of the provisions of this Agreement or the breach thereof shall be
construed to be a waiver of any subsequent or prior breach of the same or any other provision of this Agreement. Furthermore, in case of waiver of a particular provision, all other provisions of this Agreement will continue in full force and effect.

  
 13 

 15.    Force Majeure. Neither Party shall be
responsible or liable to the other hereunder for any failure or delay in the performance of its obligations under this Agreement, other than confidentiality and payment obligations, due to any contingency beyond such Party’s reasonable control,
such as war, fire, accident or other casualty, act of terrorism, acts of third parties, or act of God (“Force Majeure Event”). In the event of a Force Majeure Event, the Party affected by such Force Majeure Event shall use reasonable
efforts, consistent with good business judgment, to eliminate, cure and overcome any of such causes and resume performance of its obligations. Such Force Majeure Event shall immediately be notified to the other Party. Should such Force Majeure Event
persist for more than ninety (90) days, the Party not affected by such Force Majeure Event shall have the right to terminate this Agreement on written notice with immediate effect. 

16.    Governing Law and Jurisdiction. This Agreement shall be construed in accordance with, and governed by, the
substantive laws of the State of New York, without regard to the conflict of law provisions. For the purpose of any disputes which cannot be settled amicably, the Parties hereby irrevocably submit to the competent state and federal courts located in
the State of New York, without restricting any rights of appeal. 
 17.    Limitation of Liability. Under no
circumstances shall either Party be liable to the other under any legal or equitable claim or cause of action, whether in contract, tort or otherwise, for indirect or consequential damages (including, without limitation, loss of profits) regardless
of whether or not such Party was informed of the possibility of such damages. 
 IN WITNESS WHEREOF, the Parties have caused their
authorized representatives to execute this Agreement on the dates of signature shown below. 
  

									
	GLYTECH LLC	 		 		 	NEURORX INC.
					
	By:	 	 /s/ Daniel C. Javitt
	 		 		 	 /s/ Jonathan C. Javitt

	Name:	 	Daniel C. Javitt, PhD, MD	 		 		 	Jonathan C. Javitt, MD, MPH
	Title:	 	Managing Member	 		 		 	CEO and President

  
 14 

 Schedule A 

DEFINITIONS 
 “Affiliate”
shall mean any person or business entity which directly or indirectly Controls, is Controlled by, or is under common Control with a Party to this Agreement. For purposes of this definition, “Control” or its derivatives shall mean
direct or indirect beneficial ownership of fifty percent (50%) or more of the voting interest in an entity, or such other relationship as, in fact, constitutes control. 

“Change of Control” shall mean, with respect to a Party, one or more transactions as a result of which: (A) any person or group of
persons, becomes (directly or indirectly) a beneficial owner of 50% or more of the voting securities of such Party; (B) a majority of the Board of Directors of such Party consists of individuals other than current members of its Board of
Directors, unless such new directors have been approved by a vote of the then incumbent Board of Directors; or (C) (i) the party combines with another entity and is the surviving entity, or (ii) all or substantially all of the assets or
business of such Party is disposed of pursuant to a sale, merger, consolidation, liquidation, dissolution or other transaction or series of transactions (collectively, a “Triggering Event”) unless the holders of voting securities of such
Party immediately prior such Triggering Event beneficially own, directly or indirectly, by reason of their ownership of voting securities of a Party immediately prior to such Triggering Event, more than 50% of the voting of such Party, in the case
of a combination in which a Party is the surviving entity, and in any other case, the entity (if any) that succeeds to substantially all of its business and assets. 

“Confidential Information” of Glytech or NeuroRx, as the case may be, shall be all proprietary and non-public technical, scientific,
regulatory, legal, commercial and other information (including, but not limited to, data, documents and results of each Party disclosed to the other Party pursuant to this Agreement). The fact that the Parties are entering into this Agreement and
the terms here of shall also constitute Confidential Information. 
 “Controlled” in relation to the subject matter with which it appears
shall mean the legal authority or right of a Party hereto (or any of its Affiliates): (i) to transfer to another Party legal title in the subject matter; (ii) to disclose to another Party proprietary, trade secret, regulatory or other
information pertaining to the subject matter; or (iii) to grant to another Party a license or sublicense to any rights in the subject matter. 

“Excluded Claims” shall mean any claims of any Patent Rights set forth on Schedule B that do not recite either D-cycloserine or
lurasidone individually or jointly. 
 “Excluded Technology” shall mean any technology, and any Know-How related thereto, covered in the
Patent Rights listed on Schedule B that does not relate specifically to compositions containing either D-cycloserine or lurasidone. 
 “Executive
Compensation” shall mean the base salary and bonus compensation paid to the Chief Executive Officer and other members of senior management of NeuroRx. 

  
 15 

 “FDA” means the United States Food and Drug Administration, or any successor entity that
may be established hereafter which has substantially the same authority or responsibility currently vested in the United States Food and Drug Administration. 

“Field” means the treatment of depression and suicide associated with bipolar disorder in humans. 

“Glytech Patent Rights” means the Licensed Patent Rights, together with all other Patent Rights of Glytech covering any Excluded Claims or
Excluded Technologies. 
 “Glytech Technology” means the Licensed Technology and any Excluded Technology. 

“Inventions” means any and all ideas, concepts, methods, procedures, processes, improvements, inventions and discoveries, whether or not
patentable, that are conceived or reduced to practice in the course of the performance of activities conducted in connection with this Agreement including the development, manufacture and commercialization of the Products. 

“Know-How” means all technical, scientific and other know-how, data, materials, information, trade secrets, ideas, formulae,
inventions, discoveries, processes, machines, manufactures, compositions of matter, improvements, protocols, techniques, works of authorship, and results of experimentation and testing (whether or not patentable), in written, electronic, oral or any
other form. 
 “License” shall mean the license granted to NeuroRx by Glytech to the Licensed Technology set forth in Section 2.1 of
this Agreement. 
 “Licensed Claims” means all claims related to use of, or methods of treatment using D-cycloserine, lurasidone or
combination products involving these compounds including methods of treatment involving bipolar disorder and associated suicidality deriving from US Patent Application Number 13/936,198, entitled Composition and Method for Treatment of Depression
and Psychosis in Humans, applications claiming priority thereto, International Patent Application Number PCT/US2013/49653, corresponding national/regional phase applications therefrom, and all divisional applications thereof developed by Glytech
and Dr. Daniel C. Javitt. 
 “Licensed Patent Rights” means only those rights to Licensed Claims included in the Patents Rights
that disclose, describe or claim subject matter relating to use of D-cycloserine, lurasidone or combination products involving these compounds in the Field, which are Controlled by Glytech or its Affiliates as of the Effective Date of this Agreement
or thereafter during the Term, including, without limitation, those contained within the Patents Rights listed on Schedule B of this Agreement. 

“Licensed Know-How” means any and all Know-How Controlled or developed by Glytech or its Affiliates as of the Effective Date of
this Agreement, or thereafter during the Term, relating to the Licensed Patent Rights. 
 “Licensed Technology” means Licensed Patent
Rights and Licensed Know-How, not including the Excluded Technology, for use in the Field. 

  
 16 

 “Net Proceeds” means shall mean all upfront licensing or sublicensing fees, milestone fees,
license maintenance fees and royalties received by Glytech or its Affiliates relating to the Licensed Technology and the Products, in each instance in the Field, less all direct out of pocket costs incurred by Glytech of its Affiliates (or by
NeuroRX prior thereto) in connection with research and development with respect to any Licensed Technology or Product in the Field, regulatory approvals for any Product in the Field, negotiation and execution of appropriate sublicense, research and
development, marketing and distribution agreements with respect to any Licensed Technology or Product in the Field, maintenance of any regulatory approvals for any Licensed Technology or Product in the Field, and direct out of pocket costs of a
similar type or nature to the foregoing as reasonably incurred by Glytech (or previously incurred by NeoroRx) in connection with any Licensed Technology or Product in the Field. 

“Original Effective Date” shall mean August 6, 2015. 

“Other Founders’ Shares” means the shares of common stock or other shares of capital stock of NeuroRx not held by Glytech, and issued
and outstanding prior to the closing of the first two financing rounds, which were completed after the Original Effective Date and prior to the date hereof. 

“Paid Up License” means, with regard to the License, that the license granted to NeuroRx by Glytech hereunder shall continue in perpetuity
unless earlier terminated in accordance with the terms of this Agreement. 
 “Party” shall mean either NeuroRx or Glytech and
“Parties” shall collectively mean NeuroRx and Glytech. 
 “Patent Rights” means: (i) any existing or future
application for a letters patent or utility model and any substitutions, divisions, and continuations or continuations-in-part thereof, (ii) any patents issued from the foregoing patent applications; (iii) any reissues, renewals,
registrations, confirmations, re-examinations, supplementary protection certificates and extensions of such patents; and (iv) all international and foreign counterparts of the foregoing. 

“Person” shall mean any individual, corporation (including any nonprofit corporation), general or limited partnership, limited liability
company, joint venture, estate, trust, association, organization, labor union, or other entity or governmental agency or body. 
 “Product”
shall mean any product developed or under development which incorporates or utilizes the Licensed Technology. 
 “Regulatory Approval”
shall mean all permissions, approvals, licenses, registrations, authorizations, or clearances of any regulatory authority that are necessary for the marketing and sale of a Product in the Territory. 

“Term” shall mean the period commencing on the Effective Date and ending in accordance with the terms of this Agreement. 

“Third Financing Round” shall mean a transaction or a series of transactions (excluding the first two financing rounds that occurred after
the Original Effective Date and prior to the 

  
 17 

 
Effective Date and the proceeds thereof) involving the issuance of Third Financing Shares of NeuroRx, or the equivalent thereof (including a transaction involving an initial public offering of
NeuroRx), resulting in aggregate gross proceeds to NeuroRx of at least $20,000,000 for the purpose of organizing and conducting, to the extent necessary to support Regulatory Approval, one or more clinical studies, including but not limited to a
pivotal trial for the first Product using the Licensed Technology. 
 “Territory” shall mean the entire world. 

  
 18 

 Schedule B 

Patent Rights 
  

															
	 Country
	  	 App. No.
	  	 Filing

Date
	  	 Pub. No.
	  	 Pub.

Date
	  	 Patent No.
	  	 Grant

Date
	  	 Status

	 US
	  	13/936198	  	7/7/13	  	2014/0018348	  	1/16/14	  	n/a	  	n/a	  	pending
	 WO
	  	PCT/US2013/49653	  	7/9/13	  	WO2014/011590	  	1/16/14	  	n/a	  	n/a	  	pending
	 CA
	  	2878565	  	7/9/13	  	2014011590	  	1/16/14	  	n/a	  	n/a	  	pending
	 AU
	  	2013288827	  	7/9/13	  	2013288827	  	2/19/15	  	n/a	  	n/a	  	pending
	 EP
	  	20130816622	  	7/9/13	  	2872139	  	5/20/15	  	n/a	  	n/a	  	pending
	 CN
	  	2013837202	  	7/9/13	  	104507477	  	4/8/15	  		  		  	(need verification)
	 IL
	  	20150236687	  	1/12/15	  	236687	  	2/26/15	  		  		  	(need verification)

 Licensed Patent Rights are rights in the Licensed Claims included within the Patent Rights listed in this Schedule B
specifically related to use of D-cycloserine, lurasidone, and combination products involving these compounds 

  
 19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]